Chimerix to Present at Virtual H.C. Wainwright Global Life Sciences Conference
March 02 2021 - 7:00AM
Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on
accelerating the development of medicines to treat cancer and other
serious diseases, today announced that Mike Sherman, Chief
Executive Officer, will participate in a pre-recorded presentation
at the H.C. Wainwright Global Life Sciences Conference made
available on Tuesday, March 9, 2021 at 7:00 a.m. ET.
An audio webcast of the presentation will be available on the
Investor Relations section of Chimerix's website at
ir.chimerix.com, where it will be archived for approximately 90
days.
About Chimerix
Chimerix is a development-stage biopharmaceutical company
dedicated to accelerating the advancement of innovative medicines
that make a meaningful impact in the lives of patients living with
cancer and other serious diseases. Our three most advanced
clinical-stage development programs are BCV, ONC201 and DSTAT. BCV
is an antiviral drug candidate developed as a potential medical
countermeasure for smallpox and is currently under review for
regulatory approval in the United States. ONC201 is currently in a
registrational clinical program for recurrent H3 K27M-mutant glioma
and a confirmatory response rate assessment is expected later this
year. DSTAT is in development as a potential first-line therapy in
acute myeloid leukemia and as a potential treatment for acute lung
injury in hospitalized COVID-19 patients.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to risks and uncertainties that could cause actual
results to differ materially from those projected. Forward-looking
statements include those relating to, among other things,
Chimerix’s ability to obtain regulatory approval for BCV; the
timing and receipt of a potential procurement contract for BCV in
smallpox; and the timing of enrollment in the DSTAT trial for AML.
Among the factors and risks that could cause actual results to
differ materially from those indicated in the forward-looking
statements are risks that BCV may not obtain regulatory approval
from the FDA or such approval may be delayed or conditioned; risks
that Chimerix will not obtain a procurement contract for BCV in
smallpox in a timely manner or at all; risks related to the timing
and conduct of the DSTAT trials for AML and COVID; risks that
ongoing or future trials may not be successful or replicate
previous trial results, or may not be predictive of real-world
results or of results in subsequent trials; risks and uncertainties
relating to competitive products and technological changes that may
limit demand for our drugs; risks that our drugs may be precluded
from commercialization by the proprietary rights of third parties;
and additional risks set forth in the Company's filings with
the Securities and Exchange Commission. These forward-looking
statements represent the Company's judgment as of the date of this
release. The Company disclaims, however, any intent or obligation
to update these forward-looking statements.
CONTACT:Investor
Relations: Michelle
LaSpaluto919 972-7115ir@chimerix.comWill O’ConnorStern Investor
Relations212-362-1200will@sternir.com
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Apr 2024 to May 2024
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From May 2023 to May 2024